Dr. Michael Henderson serves as the Chief Executive Officer and Director of Apogee Therapeutics, guiding the biotechnology enterprise through its clinical trials, strategic financing collaborations, and eventual acquisition agreement with AbbVie. Bringing extensive background experience in life sciences business development and drug creation, he oversees the company's executive management and scientific research strategies.